Endoscopic ultrasonography-guided gastroenterostomy versus surgical gastrojejunostomy for palliation of malignant gastric outlet obstruction (ENDURO) : study protocol for a randomized controlled trial
© 2023. BioMed Central Ltd., part of Springer Nature..
BACKGROUND: Malignant gastric outlet obstruction (GOO) is a debilitating condition that frequently occurs in patients with malignancies of the distal stomach and (peri)ampullary region. The standard palliative treatment for patients with a reasonable life expectancy and adequate performance status is a laparoscopic surgical gastrojejunostomy (SGJ). Recently, endoscopic ultrasound-guided gastroenterostomy (EUS-GE) emerged as a promising alternative to the surgical approach. The present study aims to compare these treatment modalities in terms of efficacy, safety, and costs.
METHODS: The ENDURO-study is a multicentre, open-label, parallel-group randomized controlled trial. In total, ninety-six patients with gastric outlet obstruction caused by an irresectable or metastasized malignancy will be 1:1 randomized to either SGJ or EUS-GE. The primary endpoint is time to tolerate at least soft solids. The co-primary endpoint is the proportion of patients with persisting or recurring symptoms of gastric outlet obstruction for which a reintervention is required. Secondary endpoints are technical and clinical success, quality of life, gastroenterostomy dysfunction, reinterventions, time to reintervention, adverse events, quality of life, time to start chemotherapy, length of hospital stay, readmissions, weight, survival, and costs.
DISCUSSION: The ENDURO-study assesses whether EUS-GE, as compared to SGJ, results in a faster resumption of solid oral intake and is non-inferior regarding reinterventions for persistent or recurrent obstructive symptoms in patients with malignant GOO. This trial aims to guide future treatment strategies and to improve quality of life in a palliative setting.
TRIAL REGISTRATION: International Clinical Trials Registry Platform (ICTRP): NL9592. Registered on 07 July 2021.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:24 |
|---|---|
| Enthalten in: |
Trials - 24(2023), 1 vom: 25. Sept., Seite 608 |
| Sprache: |
Englisch |
|---|
| Links: |
|---|
| Themen: |
Clinical Trial Protocol |
|---|
| Anmerkungen: |
Date Completed 27.09.2023 Date Revised 18.11.2023 published: Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1186/s13063-023-07522-7 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM362459665 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM362459665 | ||
| 003 | DE-627 | ||
| 005 | 20231226091305.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1186/s13063-023-07522-7 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1208.xml |
| 035 | |a (DE-627)NLM362459665 | ||
| 035 | |a (NLM)37749590 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Kastelijn, Janine B |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Endoscopic ultrasonography-guided gastroenterostomy versus surgical gastrojejunostomy for palliation of malignant gastric outlet obstruction (ENDURO) |b study protocol for a randomized controlled trial |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 27.09.2023 | ||
| 500 | |a Date Revised 18.11.2023 | ||
| 500 | |a published: Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2023. BioMed Central Ltd., part of Springer Nature. | ||
| 520 | |a BACKGROUND: Malignant gastric outlet obstruction (GOO) is a debilitating condition that frequently occurs in patients with malignancies of the distal stomach and (peri)ampullary region. The standard palliative treatment for patients with a reasonable life expectancy and adequate performance status is a laparoscopic surgical gastrojejunostomy (SGJ). Recently, endoscopic ultrasound-guided gastroenterostomy (EUS-GE) emerged as a promising alternative to the surgical approach. The present study aims to compare these treatment modalities in terms of efficacy, safety, and costs | ||
| 520 | |a METHODS: The ENDURO-study is a multicentre, open-label, parallel-group randomized controlled trial. In total, ninety-six patients with gastric outlet obstruction caused by an irresectable or metastasized malignancy will be 1:1 randomized to either SGJ or EUS-GE. The primary endpoint is time to tolerate at least soft solids. The co-primary endpoint is the proportion of patients with persisting or recurring symptoms of gastric outlet obstruction for which a reintervention is required. Secondary endpoints are technical and clinical success, quality of life, gastroenterostomy dysfunction, reinterventions, time to reintervention, adverse events, quality of life, time to start chemotherapy, length of hospital stay, readmissions, weight, survival, and costs | ||
| 520 | |a DISCUSSION: The ENDURO-study assesses whether EUS-GE, as compared to SGJ, results in a faster resumption of solid oral intake and is non-inferior regarding reinterventions for persistent or recurrent obstructive symptoms in patients with malignant GOO. This trial aims to guide future treatment strategies and to improve quality of life in a palliative setting | ||
| 520 | |a TRIAL REGISTRATION: International Clinical Trials Registry Platform (ICTRP): NL9592. Registered on 07 July 2021 | ||
| 650 | 4 | |a Clinical Trial Protocol | |
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Clinical trial | |
| 650 | 4 | |a Endoscopic ultrasonography | |
| 650 | 4 | |a Gastric outlet obstruction | |
| 650 | 4 | |a Gastroenterostomy | |
| 650 | 4 | |a Gastrojejunostomy | |
| 650 | 4 | |a Malignancy | |
| 650 | 4 | |a Surgery | |
| 700 | 1 | |a van de Pavert, Yorick L |e verfasserin |4 aut | |
| 700 | 1 | |a Besselink, Marc G |e verfasserin |4 aut | |
| 700 | 1 | |a Fockens, Paul |e verfasserin |4 aut | |
| 700 | 1 | |a Voermans, Rogier P |e verfasserin |4 aut | |
| 700 | 1 | |a van Wanrooij, Roy L J |e verfasserin |4 aut | |
| 700 | 1 | |a de Wijkerslooth, Thomas R |e verfasserin |4 aut | |
| 700 | 1 | |a Curvers, Wouter L |e verfasserin |4 aut | |
| 700 | 1 | |a de Hingh, Ignace H J T |e verfasserin |4 aut | |
| 700 | 1 | |a Bruno, Marco J |e verfasserin |4 aut | |
| 700 | 1 | |a Koerkamp, Bas Groot |e verfasserin |4 aut | |
| 700 | 1 | |a Patijn, Gijs A |e verfasserin |4 aut | |
| 700 | 1 | |a Poen, Alexander C |e verfasserin |4 aut | |
| 700 | 1 | |a van Hooft, Jeanin E |e verfasserin |4 aut | |
| 700 | 1 | |a Inderson, Akin |e verfasserin |4 aut | |
| 700 | 1 | |a Mieog, J Sven D |e verfasserin |4 aut | |
| 700 | 1 | |a Poley, Jan-Werner |e verfasserin |4 aut | |
| 700 | 1 | |a Bijlsma, Alderina |e verfasserin |4 aut | |
| 700 | 1 | |a Lips, Daan J |e verfasserin |4 aut | |
| 700 | 1 | |a Venneman, Niels G |e verfasserin |4 aut | |
| 700 | 1 | |a Verdonk, Robert C |e verfasserin |4 aut | |
| 700 | 1 | |a van Dullemen, Hendrik M |e verfasserin |4 aut | |
| 700 | 1 | |a Hoogwater, Frederik J H |e verfasserin |4 aut | |
| 700 | 1 | |a Frederix, Geert W J |e verfasserin |4 aut | |
| 700 | 1 | |a Molenaar, I Quintus |e verfasserin |4 aut | |
| 700 | 1 | |a Welsing, Paco M J |e verfasserin |4 aut | |
| 700 | 1 | |a Moons, Leon M G |e verfasserin |4 aut | |
| 700 | 1 | |a van Santvoort, Hjalmar C |e verfasserin |4 aut | |
| 700 | 1 | |a Vleggaar, Frank P |e verfasserin |4 aut | |
| 700 | 0 | |a Dutch Pancreatic Cancer Group |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Trials |d 2006 |g 24(2023), 1 vom: 25. Sept., Seite 608 |w (DE-627)NLM161320430 |x 1745-6215 |7 nnns |
| 773 | 1 | 8 | |g volume:24 |g year:2023 |g number:1 |g day:25 |g month:09 |g pages:608 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1186/s13063-023-07522-7 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 24 |j 2023 |e 1 |b 25 |c 09 |h 608 | ||